PMID- 38367320
OWN - NLM
STAT- MEDLINE
DCOM- 20240401
LR  - 20240401
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 172
DP  - 2024 Apr
TI  - Adjunctive cariprazine as a novel effective strategy for treating major 
      depressive disorder: A systematic review and meta-analysis.
PG  - 71-80
LID - S0022-3956(24)00081-5 [pii]
LID - 10.1016/j.jpsychires.2024.02.018 [doi]
AB  - BACKGROUND: Cariprazine has been approved by the Food and Drug Administration for 
      treating bipolar depression and as an adjunctive treatment for Major Depressive 
      Disorder (MDD). However, it remains unclear about its pharmacological efficacy in 
      treating MDD. Therefore, a meta-analysis was conducted to investigate the 
      adjunctive use of cariprazine in MDD. METHODS: Electronic databases were searched 
      for eligible studies evaluating the efficacy and safety of cariprazine in 
      patients with MDD up to November 15, 2023. The changes in Montgomery-Asberg 
      Depression Rating Scale (MADRS) score and incidence of adverse events (AEs), 
      which represents of efficacy and tolerability, are considered as the main 
      outcomes. RESULTS: A total of 3066 patients with MDD included in all across 5 
      RCTs. With regard to MADRS score, cariprazine group showed better results than 
      control group (SMD = -0.12, 95% CI -0.19 to -0.04, P = 0.002, 5 RCTs, n = 3066). 
      Cariprazine, meanwhile, improved the MADRS response (RR = 1.19, 95% CI 1.08 to 
      1.31, P = 0.0004, 5 RCTs, n = 3066). For safety outcomes, statistical difference 
      was observed in AEs (RR = 1.26, 95% CI 1.18 to 1.35, P < 0.00001, 5 RCTs, 
      n = 3077). The suicide ideation and SAEs showed no statistical difference between 
      two groups. CONCLUSION: Cariprazine demonstrated antidepressant effect as an 
      augmentation therapy in treating MDD. Meanwhile, the tolerability of it was 
      acceptable as an adjunctive treatment. However, studies with larger sample sizes 
      are still needed to explore the optimal dosage.
CI  - Copyright (c) 2024 Elsevier Ltd. All rights reserved.
FAU - Xie, Minjia
AU  - Xie M
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China.
FAU - Qiu, Youjia
AU  - Qiu Y
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China.
FAU - Wang, Menghan
AU  - Wang M
AD  - Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, 215002, 
      China.
FAU - Wei, Xingzhou
AU  - Wei X
AD  - Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, 215002, 
      China.
FAU - Tao, Yuchen
AU  - Tao Y
AD  - Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, 215002, 
      China.
FAU - Duan, Aojie
AU  - Duan A
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China.
FAU - Shang, Jing
AU  - Shang J
AD  - Department of Psychiatry, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China. Electronic address: gaowei_2023@163.com.
FAU - Wang, Zhong
AU  - Wang Z
AD  - Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 
      Suzhou, Jiangsu Province, 215006, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20240208
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - F6RJL8B278 (cariprazine)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Piperazines)
SB  - IM
MH  - Humans
MH  - *Depressive Disorder, Major/drug therapy/chemically induced
MH  - *Antipsychotic Agents/adverse effects
MH  - Antidepressive Agents/adverse effects
MH  - Piperazines/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cariprazine
OT  - Depression
OT  - Major depressive disorder
OT  - Meta-analysis
COIS- Declaration of competing interest The authors declared that there is no conflict 
      of interest in this manuscript.
EDAT- 2024/02/18 00:42
MHDA- 2024/04/01 06:43
CRDT- 2024/02/17 18:02
PHST- 2023/07/08 00:00 [received]
PHST- 2023/12/14 00:00 [revised]
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/04/01 06:43 [medline]
PHST- 2024/02/18 00:42 [pubmed]
PHST- 2024/02/17 18:02 [entrez]
AID - S0022-3956(24)00081-5 [pii]
AID - 10.1016/j.jpsychires.2024.02.018 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2024 Apr;172:71-80. doi: 10.1016/j.jpsychires.2024.02.018. Epub 
      2024 Feb 8.